NK-92/5.28.z cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NK-92/5.28.z cells, covering 2026-04-23 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma [Phase 1]